<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03788382</url>
  </required_header>
  <id_info>
    <org_study_id>FATAPANC</org_study_id>
    <nct_id>NCT03788382</nct_id>
  </id_info>
  <brief_title>Failure to Adjuvant Therapy After Pancreatic Resection for Pancreatic Cancer</brief_title>
  <official_title>Failure to Adjuvant Therapy After Pancreatic Resection for Pancreatic Cancer: a Real Life Scenario</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universita di Verona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universita di Verona</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the rate of patients submitted to pancreatic resection for
      pancreatic cancer, who fail to access to adjuvant therapy or do not complete adjuvant
      therapy. The purpose is to give an overview concerning the most frequent conditions and/or
      reasons associated with failure or omission of adjuvant therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective observational study will evaluate all patients submitted to pancreatic
      resection for pancreatic cancer.

      The rate of omission to adjuvant therapy and rate of failure of completion of adjuvant
      therapy will be evaluated as primary outcomes. As secondary outcomes, survival analyses will
      be performed to investigate whether these factors influence prognosis, that will be evaluated
      through a disease free survival analysis at 18-months. Epidemiological and perioperative data
      will be analyzed to identify conditions associated with the primary outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of patients who fail to receive adjuvant therapy and reasons for that</measure>
    <time_frame>6 months</time_frame>
    <description>The amount of patients who will not receive adjuvant therapy after pancreatic resection for malignancy (when do indication exists) will be recorded</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of patients who fail to complete adjuvant therapy and reasons for that</measure>
    <time_frame>9 months</time_frame>
    <description>The amount of patients who will not complete adjuvant therapy after pancreatic resection for malignancy will be recorded</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease free survival of patients enrolled</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Pancreatic Malignant Neoplasm Primary</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients submitted to Pancreatic Resection for Pancreatic Cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologic diagnosis of pancreatic cancer

        Exclusion Criteria:

          -  Non exocrine pancreatic tumors

          -  Periampullary malignancies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Verona Hospital</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salvatore Paiella, MD</last_name>
      <phone>00393283342248</phone>
      <email>salvatore.paiella@univr.it</email>
    </contact>
    <investigator>
      <last_name>Salvatore Paiella, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicola Quintarelli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claudio Bassi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roberto Salvia, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alice Cattelani, Med Stud</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 21, 2018</study_first_submitted>
  <study_first_submitted_qc>December 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 27, 2018</study_first_posted>
  <last_update_submitted>March 1, 2020</last_update_submitted>
  <last_update_submitted_qc>March 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universita di Verona</investigator_affiliation>
    <investigator_full_name>Salvatore Paiella, MD</investigator_full_name>
    <investigator_title>Salvatore Paiella, MD, Universit√† di Verona</investigator_title>
  </responsible_party>
  <keyword>Failure Adjuvant Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

